Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01683474
Other study ID # Venus-A Study
Secondary ID
Status Recruiting
Phase N/A
First received September 7, 2012
Last updated January 3, 2015
Start date September 2012
Est. completion date April 2016

Study information

Verified date January 2015
Source Venus MedTech (HangZhou) Inc.
Contact Runlin Gao, MD
Phone 88398866
Email gaorunlin4study@gmail.com
Is FDA regulated No
Health authority China: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

1. objectives

- Evaluate the performance of Venus MedTech aortic valve prosthesis intervention by femoral artery

- Evaluate safety and clinical benefit of percutaneous implantation of the Venue MedTech aortic valve prosthesis.

- Continuous observe 12 months of safety and efficacy.

2. Approximately 80 patients presenting with native aortic valve stenosis necessitating valve replacement which are considered unsuitable for Surgical Valve Replacement, with a high surgical risk, as attested to by both the surgeon and the cardiologist are recruited in the study.

3. Safety and performance will be evaluated at discharge and at 30 days post procedure. Valve safety, performance and placement will be followed up at 6 and 12 months post-procedure.


Description:

A prospective OPC study to evaluate its performance and long-term safety and effectiveness of Venus-A aortic valve.


Recruitment information / eligibility

Status Recruiting
Enrollment 80
Est. completion date April 2016
Est. primary completion date February 2016
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Senile degenerative aortic valve stenosis with echocardiography derived criteria: mean gradient = 40 mm Hg, or jet velocity = 4.0 m/s, or an aortic valve area (AVA) of < 0.8 cm2 (or AVA index < 0.5 cm2/m2)

- Symptomatic due to aortic valve stenosis as demonstrated by NYHA Functional Class = II

- The subject or the subject's legal representative was informed of the nature of the study, agreed to its provisions and provided written informed consent as approved by the Institutional Review Board of the respective clinical site.

- The subject agreed to comply follow-up evaluation

- is evaluated by at least one cardiologist and two cardiovascular surgeon, and they agreed that medical factors precluding operation suitable for surgery (the probability of death or serious, irreversible morbidity exceeded 50%)

- STS score = 10%

Exclusion Criteria:

- Patient refuses aortic valve replacement surgery.

- Evidence of an acute myocardial infarction = 1 month before the intended treatment [defined as: Q wave MI, or non-Q wave MI with total CK elevation of CK-MB = twice normal in the presence of MB elevation and/or troponin level elevation (WHO definition)].

- Aortic valve is a congenital unicuspid or congenital bicuspid valve, or is non-calcified.

- Mixed aortic valve disease (aortic stenosis and aortic regurgitation with predominant aortic regurgitation >3+).

- Any therapeutic invasive cardiac procedure resulting in a permanent implant that is performed within 30 days (6 month if DES implant)

- Implanted any heart valve prosthesis, prosthetic valve ring, severe mitral valve ring calcification (MAC), severe(>3+)mitral valve insufficiency, or Gorelin symptom

- Blood dyscrasia such as leukopenia (WBC < 3×109/L), acute anemia (Hgb < 90 g/L), thrombocytopenia (PLT < 50×109/L), bleeding diathesis, or history of coagulopathy.

- Untreated clinically significant coronary artery disease requiring revascularization

- Hemodynamic instability requiring inotropic therapy or mechanical hemodynamic support devices

- Need for emergency surgery for any reason

- Hypertrophic cardiomyopathy with or without obstruction (HOCM)

- Severe ventricular dysfunction with LVEF < 20%

- Echocardiographic evidence of intracardiac mass, thrombus or vegetation

- Active peptic ulcer or upper gastro-intestinal bleeding within the prior 3 months

- A known hypersensitivity or contraindication to aspirin, heparin, ticlopidine, clopidogrel, Nitinol, or sensitivity to contrast media which cannot be adequately pre-medicated.

- Native aortic annulus size < 20 mm or> 29 mm as measured by echocardiogram.

- Cerebrovascular Accident (CVA) within 6 months, including TIA.

- Renal insufficiency (creatinine > 3.0 mg/dL) and/or end stage renal disease requiring chronic dialysis.

- Life expectancy < 12 months

- Significant abdominal or thoracic aorta disease, including aneurysm (defined as maximal luminal diameter 5cm or greater), marked tortuosity (hyperacute bend), aortic arch atheroma (especially if thick [> 5 mm], protruding or ulcerated), narrowing of the abdominal aorta (especially with calcification and surface irregularities), or severe "unfolding" and tortuosity of the thoracic aorta

- Iliofemoral vessel characteristics that would preclude safe placement of 16F or 18F introducer sheath such as severe obstructive calcification, severe tortuosity or vessel size diameter < 7 mm.

- Currently participating in an investigational drug or another device study.

- Active bacterial endocarditis or other active infections.

- Bulky calcified aortic valve leaflets in close proximity to coronary ostia

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Device:
Venus MedTech Aortic Valve Prosthesis
Percutaneous implantation of aortic valve of Venus-A

Locations

Country Name City State
China Fu Wai Hospital, CAMS & PUMA Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Venus MedTech (HangZhou) Inc.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary All cause mortality and major stroke at 12 months post-procedure. 12 months post-procedure Yes
Secondary Valve performance and placement at 6 and 12 months post-procedure 6 and 12 months post-procedure No
See also
  Status Clinical Trial Phase
Completed NCT03186339 - Validation of the "TASQ" in Patients Undergoing SAVR or TF-TAVI
Recruiting NCT03549559 - Imaging Histone Deacetylase in the Heart N/A
Terminated NCT02854319 - REpositionable Percutaneous Replacement of NatIve StEnotic Aortic Valve Through Implantation of LOTUS EDGE Valve System N/A
Recruiting NCT05601453 - The ReTAVI Prospective Observational Registry
Withdrawn NCT05481814 - CPX in Paradoxical Low Flow Aortic Stenosis
Completed NCT02241109 - Predicting Aortic Stenosis Progression by Measuring Serum Calcification Propensity N/A
Completed NCT01700439 - Surgical Treatment of Aortic Stenosis With a Next Generation, Rapid Deployment Surgical Aortic Valve N/A
Recruiting NCT04429035 - SLOW-Slower Progress of caLcificatiOn With Vitamin K2 N/A
Completed NCT04103931 - Impact of a Patient Decision Aid for Treatment of Aortic Stenosis N/A
Completed NCT03950440 - Assessing the Incidence of Postoperative Delirium Following Aortic Valve Replacement
Active, not recruiting NCT02661451 - Transcatheter Aortic Valve Replacement to UNload the Left Ventricle in Patients With ADvanced Heart Failure (TAVR UNLOAD) N/A
Completed NCT02847546 - Evaluation of the BARD® True™ Flow Valvuloplasty Perfusion Catheter for Aortic Valve Dilatation N/A
Completed NCT02792452 - Clinical Value of Stress Echocardiography in Moderate Aortic Stenosis
Completed NCT02758964 - Evaluation of Cerebral Thrombembolism After TAVR
Not yet recruiting NCT02541877 - Sizing-sTrategy of Bicuspid AoRtic Valve Stenosis With Transcatheter Self-expandable Valve Phase 3
Not yet recruiting NCT02536703 - Safety and Efficacy of Lotus Valve For TAVI In Patients With Severe Aortic Stenosis In Chinese Population Phase 3
Completed NCT02249000 - BIOVALVE - I / II Clincial Investigation N/A
Not yet recruiting NCT02221921 - Safety and Efficacy Study of MicroPort's Transcatheter Aortic Valve and Delivery System for TAVI N/A
Active, not recruiting NCT02080299 - Protection by Remote Ischemic Preconditioning During Transcatheter Aortic Valve Implantation Phase 2
Terminated NCT01939678 - Characterization and Role of Mutations in Sodium-phosphate Cotransporters in Patients With Calcific Aortic Valve Disease